KDC-MN-197 – Kodiac biolabs

Plain-language summaryIntrigue 55 / 100

Niacin (nicotinic acid) is vitamin B3 in its acid form, distinct from nicotinamide. It causes flushing (a vasodilatory side effect) at therapeutic doses. Used historically for high cholesterol and as a NAD+ precursor. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundGeneric nutrient

27/100

Mature vitamin B3 with real lipid biology but outclassed in every modern research context

Cap applied Generic vitamin cap (28)

Look, niacin is vitamin B3. It has been in the pharmacopoeia since before most working scientists were born, and thats not a knock on it as a nutrient. It’s just the honest truth about where it sits in the research conversation in 2026.

The high-dose lipid story had real momentum from the 1970s through the early 2000s. Niacin genuinely lowers LDL, raises HDL, and reduces triglycerides via hepatic VLDL synthesis suppression, and that mechanism is not contested. The problem is that AIM-HIGH (2011, NEJM) and HPS2-THRIVE (2014, NEJM) both showed that adding extended-release niacin to statin therapy produced no reduction in major cardiovascular events. The lipid numbers moved; the outcomes didn’t. That’s a decisive translational failure for the indication that drove decades of clinical interest, and the field has largely moved on.

The flushing mechanism is actually the more pharmacologically interesting angle. Prostaglandin D2 release from Langerhans cells via GPR109A activation is well-defined, and niacin remains the canonical GPR109A agonist. Some groups have used this as a dermal inflammation probe. Laropiprant, the DP1 receptor antagonist that Merck co-formulated to suppress flushing, generated its own research trail before that combination was pulled for safety reasons. So there’s a narrow niche-probe story here, but it’s genuinely narrow.

The NAD+ precursor angle is where you’d hope niacin might find modern relevance, but it loses badly to NMN and NR in that competition. Nicotinamide riboside and mononucleotide bypass the rate-limiting NAMPT step more efficiently and without triggering GPR109A. If your research program is about NAD+ biology, sirtuin activation, mitochondrial function, or aging, niacin isnt the compound you reach for. The frontier precursor literature is being built on those other forms, not on plain nicotinic acid.

What we don’t like: there’s no open research question in 2026 where plain niacin is the tool of choice. It’s either historically important in a space where outcomes data disappointed, trivially established as a nutrient, or outclassed as a NAD+ precursor. The niacinamide distinction adds a layer of formulation complexity without opening new research directions.

What we’ll give it: the GPR109A agonism reference-probe utility is real for labs specifically studying that receptor or prostaglandin-mediated skin biology. The evidence base is large and the pharmacology is clean. But the evidence base is large because the compound is old, not because the open questions are exciting. For a library designed to surface compounds worth bench time right now, niacin earns a slot as a reference standard and historical marker, not as a priority target.

Novelty: 10
Mechanism promise: 18
In-category differentiation: 12
Evidence quality: 68
Translational signal: 42
Research bench value: 22

Rationale Plain nicotinic acid is an essential vitamin with well-understood mechanisms; the high-dose dyslipidemia indication is mature and outcome-trial-disproven for CV benefit, and the NAD+ precursor angle is dominated by NMN and NR. No novel indication with real signal exists that would lift the generic-vitamin cap, and the raw weighted score (approx 27) falls within the cap anyway.

Vitamin B3 / NAD+ precursor

Vitamin B3 used at high doses for dyslipidemia and at low doses as an essential nutrient and NAD+ precursor.

Abstract

Niacin (nicotinic acid; CAS 59-67-6; molecular formula C6H5NO2; molecular weight 123.11) is vitamin B3, used at low doses (10 to 30 mg/day) as an essential nutrient and NAD+ precursor, and at high doses (1 to 3 grams per day) for dyslipidemia management. The high-dose niacin lipid effect (LDL reduction, HDL elevation, triglyceride reduction) is mediated through hepatic VLDL synthesis effects. The flushing response (cutaneous vasodilation, warmth, itching) at high doses is a prostaglandin-mediated effect that can be mitigated by aspirin pre-treatment or by use of immediate-release formulations with gradual titration. Niacinamide (nicotinamide) does not produce flushing but lacks the lipid effects.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-197Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-197

Niacin (Nicotinic Acid)

Abstract

Read the full monograph